195 related articles for article (PubMed ID: 24675684)
1. Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathways.
Dong X; Li R; Xiu P; Dong X; Xu Z; Zhai B; Liu F; Jiang H; Sun X; Li J; Qiao H
PLoS One; 2014; 9(3):e92864. PubMed ID: 24675684
[TBL] [Abstract][Full Text] [Related]
2. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
[TBL] [Abstract][Full Text] [Related]
3. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
Li J; Chen X; Dong X; Xu Z; Jiang H; Sun X
J Gastroenterol Hepatol; 2006 Dec; 21(12):1814-20. PubMed ID: 17074019
[TBL] [Abstract][Full Text] [Related]
4. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Kern MA; Schubert D; Sahi D; Schöneweiss MM; Moll I; Haugg AM; Dienes HP; Breuhahn K; Schirmacher P
Hepatology; 2002 Oct; 36(4 Pt 1):885-94. PubMed ID: 12297835
[TBL] [Abstract][Full Text] [Related]
5. Blocking autophagy enhances meloxicam lethality to hepatocellular carcinoma by promotion of endoplasmic reticulum stress.
Zhong J; Dong X; Xiu P; Wang F; Liu J; Wei H; Xu Z; Liu F; Li T; Li J
Cell Prolif; 2015 Dec; 48(6):691-704. PubMed ID: 26481188
[TBL] [Abstract][Full Text] [Related]
6. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
Naruse T; Nishida Y; Hosono K; Ishiguro N
Carcinogenesis; 2006 Mar; 27(3):584-92. PubMed ID: 16219634
[TBL] [Abstract][Full Text] [Related]
7. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of MiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4.
Wei X; Liu H; Li X; Liu X
Ann Hepatol; 2019; 18(6):869-878. PubMed ID: 31477445
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
Ogunwobi OO; Liu C
Clin Exp Metastasis; 2011 Dec; 28(8):721-31. PubMed ID: 21744257
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
Bourn J; Cekanova M
Drug Des Devel Ther; 2018; 12():1727-1742. PubMed ID: 29942116
[TBL] [Abstract][Full Text] [Related]
11. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice.
Kern MA; Schöneweiss MM; Sahi D; Bahlo M; Haugg AM; Kasper HU; Dienes HP; Käferstein H; Breuhahn K; Schirmacher P
Carcinogenesis; 2004 Jul; 25(7):1193-9. PubMed ID: 14963015
[TBL] [Abstract][Full Text] [Related]
13. COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells.
Teh SH; Hill AK; Foley DA; McDermott EW; O'Higgins NJ; Young LS
J Cell Biochem; 2004 Mar; 91(4):796-807. PubMed ID: 14991771
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine Induces Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits ERK/NF-κB-Modulated Anti-Apoptotic and Invasive Potential in Hepatocellular Carcinoma Cells In Vitro.
Chen WT; Hsu FT; Liu YC; Chen CH; Hsu LC; Lin SS
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30754643
[TBL] [Abstract][Full Text] [Related]
15. Meloxicam inhibits the growth of non-small cell lung cancer.
Tsubouchi Y; Mukai S; Kawahito Y; Yamada R; Kohno M; Inoue K; Sano H
Anticancer Res; 2000; 20(5A):2867-72. PubMed ID: 11062695
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway.
He C; Wu T; Hao Y
Biochem Biophys Res Commun; 2018 Sep; 503(4):3093-3099. PubMed ID: 30146257
[TBL] [Abstract][Full Text] [Related]
18. Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells.
Shu G; Xie B; Ren F; Liu DC; Zhou J; Li Q; Chen J; Yuan L; Zhou J
Cell Oncol (Dordr); 2013 Apr; 36(2):121-9. PubMed ID: 23248036
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells.
Naruse T; Nishida Y; Ishiguro N
Biomed Pharmacother; 2007 Jul; 61(6):338-46. PubMed ID: 17395421
[TBL] [Abstract][Full Text] [Related]
20. The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.
Lampiasi N; Foderà D; D'Alessandro N; Cusimano A; Azzolina A; Tripodo C; Florena AM; Minervini MI; Notarbartolo M; Montalto G; Cervello M
Int J Mol Med; 2006 Feb; 17(2):245-52. PubMed ID: 16391822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
